Abstract
The purpose of this study was to compare key hospitalization outcomes and cost between percutaneous ablation and external beam radiation therapy (EBRT) among patients admitted with acute cancer-related pain. The Merative MarketScan Research Database was queried for all cancer-related hospitalizations from 2009 to 2022 for patients who underwent percutaneous palliative ablation or EBRT for painful bone or soft tissue tumors. Hospital length of stay (LOS), 30-day readmission rate, in-hospital mortality, and total hospitalization costs from the payor perspective were compared using multivariable generalized linear models controlling for patient demographics, comorbid conditions, geographic location, and calendar year. Sensitivity analyses were conducted using different model specifications and coarsened exact matching. Amongst 19,793 hospitalizations, patients underwent ablation in 185 (0.9%) cases, and EBRT in 19,608 (99.1%). Compared to EBRT, ablation was associated with shorter LOS (-2.0 days; 95% confidence interval [CI]: -3.9 to -0.03; p = .046), lower risk of in-hospital mortality (-3.4 percentage points [p.p.]; 95% CI: -5.6 to -1.3; p = .002), lower risk of 30-day readmission (-7.4 p.p.; 95% CI: -13.7 to -1.2; p = .019), and no statistically significant difference in total hospitalization costs ($8,379; 95% CI: -1,947 to 18,706; p = .11). Less than 1% of patients hospitalized with acute cancer-related pain and treated with tumor-directed therapy (either via radiation oncology or IR) undergo percutaneous tumor ablation. In this study, percutaneous ablation was associated with shorter LOS, lower risk of in-hospital mortality, and lower risk of 30-day readmission.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call